ResearcherIstanbul Medeniyet UniversityNo recent work listed

Seval Ay Ersoy

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-7555-2657; OpenAlex author ID A5083552699. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 2

Papers, trials and grants by year

2022: 1 paper

Papers 1

FOLFIRINOX versus gemcitabine plus nab-paclitaxel as the first-line chemotherapy in metastatic pancreatic cancer. Co-author DOI 10.1080/1120009x.2022.2026125 ↗

Closest collaborators

The 2 strongest of 2 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Didem Taştekin · 1 shared paper, 2022 · strength 0.15
- Paper FOLFIRINOX versus gemcitabine plus nab-paclitaxel as the first-line chemotherapy in metastatic pancreatic cancer. DOI 10.1080/1120009x.2022.2026125 ↗
Mahmut Gümüş · 1 shared paper, 2022 · strength 0.15
- Paper FOLFIRINOX versus gemcitabine plus nab-paclitaxel as the first-line chemotherapy in metastatic pancreatic cancer. DOI 10.1080/1120009x.2022.2026125 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.